Intraoperative mitomycin C and the corneal endothelium.
OBJECTIVE
Mitomycin-C (MMC) is a useful adjunct to high risk glaucoma surgery. No clinical data regarding the deleterious effect of mitomycin-C on the corneal endothelial cells are available.


METHODS
Thirty eyes of 28 adult patients with high risk glaucomas were randomized to three groups. Group-I underwent a trabeculectomy alone, Group II, trabeculectomy with intraoperative 0.2mg/ml MMC and Group III, trabeculectomy with intraoperative 0.4mg/ml MMC. Preoperative and 3-month postoperative corneal endothelial cell counts were analysed.


RESULTS
The percentage cell loss in Group I was 3.73+/-2.73%, in Group II 13.90+/-4.69% and in Group III 14.52+/-7.8%. Statistical analysis revealed a significant difference in cell loss between Group I and Group II and Group I and Group III, but not between Group II and Group III.


CONCLUSIONS
There is a significant loss of corneal endothelial cells three months after trabeculectomy with adjunctive MMC.
Sihota
R
R
Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi.
Sharma
T
T
Agarwal
H C
HC
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002452:Cell Count / Q000187:drug effects; D017024:Chemotherapy, Adjuvant; D004728:Endothelium, Corneal / Q000187:drug effects* / Q000473:pathology; D005260:Female; D005901:Glaucoma / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D007430:Intraoperative Care; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D014130:Trabeculectomy
D016685:Mitomycin